MA43529A - Modulateurs de transport nucléaire et leurs utilisations - Google Patents
Modulateurs de transport nucléaire et leurs utilisationsInfo
- Publication number
- MA43529A MA43529A MA043529A MA43529A MA43529A MA 43529 A MA43529 A MA 43529A MA 043529 A MA043529 A MA 043529A MA 43529 A MA43529 A MA 43529A MA 43529 A MA43529 A MA 43529A
- Authority
- MA
- Morocco
- Prior art keywords
- nuclear transport
- transport modulators
- modulators
- nuclear
- transport
- Prior art date
Links
- 230000025308 nuclear transport Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273857P | 2015-12-31 | 2015-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43529A true MA43529A (fr) | 2018-11-07 |
Family
ID=57799957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043529A MA43529A (fr) | 2015-12-31 | 2016-12-30 | Modulateurs de transport nucléaire et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10526295B2 (fr) |
| EP (1) | EP3397633A1 (fr) |
| MA (1) | MA43529A (fr) |
| WO (1) | WO2017117529A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI574957B (zh) | 2011-07-29 | 2017-03-21 | 佳佑製藥治療公司 | 含有醯肼的核運輸調控子及其用途 |
| RS58058B1 (sr) | 2012-05-09 | 2019-02-28 | Biogen Ma Inc | Modulatori nukleusnog transporta i njihove upotrebe |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| DK3010892T3 (en) | 2013-06-21 | 2019-04-15 | Karyopharm Therapeutics Inc | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| EP3397633A1 (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| WO2017117535A1 (fr) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| RU2756512C1 (ru) | 2018-01-10 | 2021-10-01 | ЭксДабл-ЮФАРМА ЛТД. | Пролекарства кетамина, его композиции и применения |
| WO2019232724A1 (fr) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Composés en tant que modulateurs de transport nucléaire et leurs utilisations |
| MX2021013211A (es) | 2019-05-01 | 2022-03-11 | Karyopharm Therapeutics Inc | Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1. |
| WO2021247447A1 (fr) * | 2020-06-01 | 2021-12-09 | Luke Klele | Compositions antivirales |
| WO2022089629A1 (fr) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | Dérivé de 1,2,4-triazole, son procédé de préparation et son utilisation |
| KR20240012445A (ko) * | 2021-05-20 | 2024-01-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 트리아졸릴 아크릴아미드의 헤테로아릴 유도체 및 결정질 형태의 합성 방법 |
| US11690811B2 (en) | 2021-08-13 | 2023-07-04 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
| CN117940409A (zh) * | 2021-09-08 | 2024-04-26 | 南京明德新药研发有限公司 | 丙烯酰胺类化合物及其应用 |
| TW202321220A (zh) * | 2021-10-29 | 2023-06-01 | 大陸商正大天晴藥業集團股份有限公司 | 含吡啶基的化合物 |
| WO2023134629A1 (fr) * | 2022-01-12 | 2023-07-20 | 上海海雁医药科技有限公司 | Régulateur de transport nucléaire et son utilisation |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017398A (en) | 1911-01-16 | 1912-02-13 | John E Folsom | Telegraph-key. |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| CN1088062C (zh) | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| EP1671966A1 (fr) | 1996-04-04 | 2006-06-21 | Shionogi & Co., Ltd. | Intermédiaires pour des dérivés de céphème |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| ATE244219T1 (de) | 1996-04-25 | 2003-07-15 | Nissan Chemical Ind Ltd | Ethylenderivate und pestizide |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| EP2083005A1 (fr) | 2000-09-29 | 2009-07-29 | TopoTarget UK Limited | Composés d'acide carbamique comportant une liaison d'amide en tant qu'inhibiteurs HDAC |
| CA2465978C (fr) | 2001-09-14 | 2015-04-07 | Soon Hyung Woo | Inhibiteurs de l'histone-deacetylase |
| AU2003287965A1 (en) | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| ZA200503967B (en) | 2002-11-01 | 2006-11-29 | Takeda Pharmaceutical | Agent for preventing or treating neuropathy |
| US7342115B2 (en) | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| CA2512886A1 (fr) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands modulant des recepteurs du type lxr |
| US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
| CN101014595A (zh) | 2004-08-11 | 2007-08-08 | 杏林制药株式会社 | 新型环状氨基苯甲酸衍生物 |
| WO2006019020A1 (fr) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | Urées de substitution |
| JPWO2006088246A1 (ja) | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Ｇｐｒ３４受容体機能調節剤 |
| TWI330639B (en) | 2005-11-15 | 2010-09-21 | Otsuka Pharma Co Ltd | Oxazole compound and pharmaceutical composition |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| EA016464B1 (ru) | 2006-03-09 | 2012-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Полициклические производные арилимидазола |
| JP5554988B2 (ja) | 2006-04-07 | 2014-07-23 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| JP5290749B2 (ja) | 2006-04-18 | 2013-09-18 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
| WO2007147336A1 (fr) | 2006-06-13 | 2007-12-27 | Shanghai Institue Of Materia Medica, Chinese Academy Of Sciences | Composés non nucléosidiques hétérocycliques, leur préparation, compositions pharmaceutiques, et leur utilisation en tant qu'agents antiviraux |
| PL2054411T3 (pl) | 2006-07-27 | 2015-02-27 | Amorepacific Corp | Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne |
| EP2090570B1 (fr) | 2006-09-05 | 2011-11-09 | Kyowa Hakko Kirin Co., Ltd. | Dérivé d'imidazole |
| EP1942104A1 (fr) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
| EP1939180A1 (fr) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale |
| US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
| EP2003118A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2 |
| AU2010271205A1 (en) | 2009-07-09 | 2012-02-09 | Moko Therapeutics Llc. | Method of wound healing and scar modulation |
| US8518968B2 (en) | 2009-12-04 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| CN103002742B (zh) | 2010-03-05 | 2016-07-13 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| CA2824808A1 (fr) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucleaire contenant des olefines et leurs utilisations |
| TWI574957B (zh) | 2011-07-29 | 2017-03-21 | 佳佑製藥治療公司 | 含有醯肼的核運輸調控子及其用途 |
| WO2013019561A1 (fr) | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| WO2013020024A2 (fr) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Composés de maléimide et méthodes de traitement |
| RS58058B1 (sr) | 2012-05-09 | 2019-02-28 | Biogen Ma Inc | Modulatori nukleusnog transporta i njihove upotrebe |
| CN102777158B (zh) | 2012-07-06 | 2014-09-10 | 西南石油大学 | 测调联动系统及其操作工艺 |
| US20160016916A1 (en) | 2013-03-15 | 2016-01-21 | Karyopharm Therapeutics Inc. | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof |
| US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
| DK3010892T3 (en) | 2013-06-21 | 2019-04-15 | Karyopharm Therapeutics Inc | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF |
| WO2014205393A1 (fr) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US11567063B2 (en) | 2013-11-15 | 2023-01-31 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Methods for assessing cell viability or predicting cell response to a treatment using cell movement |
| AU2015296322B2 (en) | 2014-07-26 | 2019-09-19 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| WO2017117535A1 (fr) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| EP3397633A1 (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Modulateurs de transport nucléaire et leurs utilisations |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
-
2016
- 2016-12-30 EP EP16826682.3A patent/EP3397633A1/fr not_active Withdrawn
- 2016-12-30 WO PCT/US2016/069492 patent/WO2017117529A1/fr not_active Ceased
- 2016-12-30 MA MA043529A patent/MA43529A/fr unknown
- 2016-12-30 US US16/066,554 patent/US10526295B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017117529A1 (fr) | 2017-07-06 |
| EP3397633A1 (fr) | 2018-11-07 |
| US10526295B2 (en) | 2020-01-07 |
| US20190016690A1 (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| FR25C1020I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3490565A4 (fr) | Modulateurs de récepteurs de chimiokine et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| EP3523294A4 (fr) | Modulateurs de calpain et leurs utilisations thérapeutiques | |
| EP3328895A4 (fr) | Anticorps anti-pd-l1 et leurs utilisations | |
| MA43530A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
| EP3334706A4 (fr) | Pillararènes et utilisations de ceux-ci | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| EP3377102A4 (fr) | Anticorps anti-pd-1 et leurs utilisations thérapeutiques | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3349802A4 (fr) | Dendrimères lipocationiques et leurs utilisations | |
| EP3383904A4 (fr) | Anticorps ctla-4 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| EP3364958A4 (fr) | Modulateurs d'interaction sestrine-gator2 et leurs utilisations | |
| EP3347020A4 (fr) | Acétamide thiénotriazoldiazépines et leurs utilisations |